Physician profile
Christopher C Harrington
NPI 1730178468
$5,534.19
in general payments reported to CMS, 2019-2025
42 companies · $2,311 in 2025
The $2,311 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $284 · 2021: $533 · 2022: $362 · 2023: $338 · 2024: $1,447 · 2025: $2,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,095.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $793.81 | 2019-2025 | |
| Novo Nordisk INC | $652.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $550.62 | 2021-2025 | |
| Lilly USA, LLC | $512.24 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $434.75 | 2022-2025 | Evenity, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $371.77 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $335.81 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $221.51 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $221.47 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $159.52 | 2019-2024 | |
| Esperion Therapeutics, INC. | $135.82 | 2021-2023 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $133.00 | 2023-2025 | |
| Exact Sciences Corporation | $111.49 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.58 | 2024-2025 | Jardiance, Tradjenta |
| Amarin Pharma, INC. | $88.14 | 2020-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Harrington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.